Long-chain cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as new components of potential non-viral vectors

被引:8
作者
Cortesi, Rita [1 ]
Bergamini, Paola [2 ]
Ravani, Laura [1 ]
Drechsler, Markus [3 ]
Costenaro, Andrea [1 ]
Pinotti, Mirko [4 ]
Campioni, Matteo [4 ]
Marvelli, Lorenza [2 ]
Esposito, Elisabetta [1 ]
机构
[1] Univ Ferrara, Dept Pharmaceut Sci, I-44121 Ferrara, Italy
[2] Univ Ferrara, Dept Chem, I-44121 Ferrara, Italy
[3] Univ Bayreuth, Bayreuth, Germany
[4] Univ Ferrara, Dept Biochem & Mol Biol, I-44121 Ferrara, Italy
关键词
PTA; Non-viral gene delivery systems; Cationic solid lipid nanoparticles (cationic SLN); Transfection; SOLID-LIPID NANOPARTICLES; GENE-THERAPY; DELIVERY-SYSTEMS; DNA; TRIALS; CANCER; LIVER;
D O I
10.1016/j.ijpharm.2012.04.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to investigate the potential of new positively charged solid lipid nanoparticles (SLN) to convey nucleic acids. The cationic character of SLN was obtained by adding as cationic molecules two different long-chain cationic phosphines (CP), namely hexadecyl-PTA iodide (CP16) and octadecyl-PTA iodide (CP18). The obtained CP-SLN are characterized by a positive charge on the surface and reproducible dimensions around 220 nm. These nanosystems are able to efficiently bind nucleic acid molecules and to protect DNA from the activity of serum nucleases up to 120 min. Lastly, in vitro experiments demonstrated that CP-SLN exhibit a quite pronounced antiproliferative effect on cultured human K562 erythroleukemic cells and a limited effect as transfecting adjuvant. These data, and particularly the ability of CP-SLN to protect DNA from degradation, encourages further studies aimed at proposing these nanosystems as a potential approach to deliver nucleic acid to cells in living organisms. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:176 / 182
页数:7
相关论文
共 28 条
[1]  
[Anonymous], 1982, Molecular cloning
[2]   Evidence for an overlapping role of CLOCK and NPAS2 transcription factors in liver circadian oscillators [J].
Bertolucci, Cristiano ;
Cavallari, Nicola ;
Colognesi, Ilaria ;
Aguzzi, Jacopo ;
Chen, Zheng ;
Caruso, Pierpaolo ;
Foa, Augusto ;
Tosini, Gianluca ;
Bernardi, Francesco ;
Pinotti, Mirko .
MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (09) :3070-3075
[3]  
Brenner Malcolm K, 2009, Hematology Am Soc Hematol Educ Program, P675, DOI 10.1182/asheducation-2009.1.675
[4]   Immune responses to adenovirus and adeno-associated virus in humans [J].
Chirmule, N ;
Propert, KJ ;
Magosin, SA ;
Qian, Y ;
Qian, R ;
Wilson, JM .
GENE THERAPY, 1999, 6 (09) :1574-1583
[5]   1,3,5-TRIAZA-7-PHOSPHATRICYCLO[3.3.1.13,7]DECANE AND DERIVATIVES [J].
Daigle, DJ ;
Decuir, TJ ;
Robertson, JB ;
Darensbourg, DJ .
INORGANIC SYNTHESES, VOL 32, 1998, 32 :40-45
[6]   SYNTHESIS OF A MONOPHOSPHORUS ANALOG OF HEXAMETHYLENETETRAMINE [J].
DAIGLE, DJ ;
PEPPERMA.AB ;
VAIL, SL .
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1974, 11 (03) :407-408
[7]   Cationic lipid-DNA complexes in gene delivery:: from biophysics to biological applications [J].
de Lima, MCP ;
Simoes, S ;
Pires, P ;
Faneca, H ;
Düzgünes, N .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (2-3) :277-294
[8]   Solid lipid nanoparticles:: Formulation factors affecting cell transfection capacity [J].
del Pozo-Rodriguez, A. ;
Delgado, D. ;
Solinis, M. A. ;
Gascon, A. R. ;
Pedraz, J. L. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 339 (1-2) :261-268
[9]  
Deng W, 2010, METHODS MOL BIOL, V610, P309, DOI 10.1007/978-1-60327-029-8_18
[10]   Gene therapy clinical trials worldwide to 2007 - an update [J].
Edelstein, Michael L. ;
Abedi, Mohammad R. ;
Wixon, Jo .
JOURNAL OF GENE MEDICINE, 2007, 9 (10) :833-842